A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Antimetabolites, Antineoplastic
  • Carcinoma, Hepatocellular
  • Cholangiocarcinoma
  • Deoxycytidine
  • Infusion Pumps, Implantable
  • Liver Neoplasms

abstract

  • Hepatic arterial infusion of gemcitabine given at doses higher or longer than the recommended systemic dose of 1,000 mg/m(2) over 30 min is well tolerated. For future studies, we recommend an infusion of 1,500 mg/m(2) at a fixed dose-rate of 10 mg/(m(2) min).

publication date

  • October 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-009-0945-5

PubMed ID

  • 19221752

Additional Document Info

start page

  • 935

end page

  • 44

volume

  • 64

number

  • 5